Akums Drugs and Pharmaceuticals

    AKUMS
    Pharma
    ₹716.15
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹10,964 Cr

    P/E
    30.14
    Day range
    ₹710.70 – ₹724.00
    52-week range
    ₹409.30 – ₹838.80
    Volume
    1.41 L
    Open
    ₹711.00
    Prev close
    ₹716.60

    Latest results · Q2 FY27(consolidated)Revenue ₹1,342 Cr+31.9%Profit ₹115 Cr+168.3%Margin 8.5%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 68 / 100

    Factor percentiles

    Value68
    Quality51
    Momentum80
    Low volatility75

    Derived metrics

    Earn. yield
    3.3%
    Graham no.
    ₹341.01
    vs Graham
    -52.4%
    ROE ÷ P/B
    2.4%
    12-1 mom.
    +66.7%
    Return / vol
    1.92
    Magic Formula
    #321
    Piotroski
    4/6
    FCF yield
    8.7%
    PEG
    0.18

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Akums Drugs and PharmaceuticalsAKUMS₹10,964 Cr30.143.328.0%15.0%15.0%0.03+31.8%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 6h ago

    Headlines about Akums Drugs and Pharmaceuticals from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    29.9
    Price / Book
    3.21
    ROE (FY26)
    8.0%
    ROCE (latest year)
    15%
    Dividend yield
    0.14%

    Moving averages (NSE)

    20-day
    ₹727.58
    Price below
    50-day
    ₹759.26
    Price below
    200-day
    ₹621.17
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +6.0%
    Profit 3Y CAGR
    +37.7%
    Revenue YoY (Sep 2026)
    +31.8%
    Profit YoY (Sep 2026)
    +167.4%
    Operating margin
    15.0%
    Net margin
    8.6%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -500 Cr0 Cr500 Cr1K Cr1.5K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%8%16%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY16FY20FY21FY22FY23FY24FY25FY26-40%-20%0%20%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,0839441,0191,0331,0101,0561,0241,0181,1601,1581,1671,342
    YoY Sales growth———-13-7——-2————
    Expenses9899418919128899628959231,0131,0069921,148
    Operating Profit9331281211219412994147152175195
    OPM %9%0.3%13%12%12%9%13%9%13%13%15%15%
    Other Income10107171926273216343029
    Interest1212131255232324242526
    Depreciation323434354540373840404143
    Profit before tax59-33879291759666100121139155
    Tax %-229%20%30%27%27%-99%32%35%32%33%27%26%
    Net Profit195-3961676615065436881101115
    EPS in Rs₹13.15₹-2.80₹4.08₹4.14₹4.14₹9.38₹4.03₹2.59₹4.21₹5.38₹6.35₹7.17

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days67

    -4 days since Mar 2021

    Inventory Days110

    +17 days since Mar 2021

    Days Payable87

    +13 days since Mar 2021

    Cash Conversion Cycle89

    -1 days since Mar 2021

    Working Capital Days66

    0 days since Mar 2021

    Strengths, risks & growth

    Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. [1]

    Strengths

    • Company is almost debt free.

    Risks

    • Stock is trading at 3.22 times its book value
    • The company has delivered a poor sales growth of 9.87% over past five years.
    • Company has a low return on equity of 9.89% over last 3 years.

    Compounded Sales Growth

    10 Years
    +10%
    5 Years
    +10%
    3 Years
    +6%
    TTM
    +18%

    Compounded Profit Growth

    10 Years
    +16%
    5 Years
    +16%
    3 Years
    +29%
    TTM
    +23%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    —
    1 Year
    +69%

    Return on Equity

    10 Years
    —
    5 Years
    +6%
    3 Years
    +10%
    Last Year
    +8%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter75.26%75.26%75.26%75.26%0.00 pp
    FII1.14%1.38%1.91%4.50%+2.59 pp
    DII14.41%14.36%13.44%11.09%-2.35 pp
    Public6.45%6.29%6.67%6.42%-0.25 pp
    Others2.73%2.73%2.73%2.73%0.00 pp

    Filed with NSE for Sept 2026: promoters 75.26%, public 22.01%

    Analysts & fund holdings

    100%
    100% recommend buy
    3 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E30.1 vs 45.2
    Sector P/B6.05

    Who holds the shares, quarter by quarter

    Mutual funds 7.79% (-2.25 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters77.4%
    • Foreign institutions4.6%
    • Mutual funds7.8%
    • Insurance0.1%
    • Other domestic institutions3.5%
    • Retail5.0%
    • Others1.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Franklin India Opportunities Fund1.75%2.02%+0.23 pp
    Franklin India Small Cap Fund1.40%1.16%+0.20 pp
    Bandhan Small Cap Fund1.17%0.37%-0.01 pp
    ICICI Pru Healthcare Fund1.06%1.65%-0.24 pp
    Nippon India Pharma Fund0.89%1.09%+0.09 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    33.0%
    Downside volatility
    29.0%
    Worst 5% of days
    3.0%
    Average of that tail
    3.9%
    Max drawdown (1Y)
    18.7%
    Below its peak
    13.0%

    Against the market

    Beta vs Nifty 50
    0.85
    Correlation
    0.35
    Relative strength (3M)
    -7.6%
    ATR (14)
    3.9%

    Return

    Return 1M
    -2.1%
    Return 3M
    -3.7%
    Return 6M
    +37.8%
    Return 1Y
    +63.2%
    vs 200-day average
    +15.3%

    Momentum

    RSI (14)
    42.5
    MACD histogram
    -0.94
    Stochastic %K
    5.7
    ADX (14)
    22.2
    +DI / −DI
    23.1 / 23.0
    Money flow index
    64.7

    Participation

    Delivery (20d avg)
    47.6%
    vs its 60-day baseline
    -3.1 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    -0.4%
    52-week position
    74 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹951 Cr
    FCF yield
    8.7%
    Cash conversion
    4.61
    Accruals ratio
    -0.170
    Net debt
    -₹67 Cr
    Net debt / equity
    -0.02
    EV / sales
    2.26
    PEG
    0.18
    Capex intensity
    5.3%
    Revenue CAGR
    31.9%
    Profit CAGR
    168.3%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹2.00

      Dividend - Re 1 Per Share/Special Dividend - Rs 2 Per Share

      3 Jul 2026
      ex-date

    Company announcements

    Insider Trading / SAST
    Closure of Trading Window
    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of the Institutional Investors Meets

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Investors/Analysts Meet

    Company Update
    ESG Rating

    Intimation of ESG Rating

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of the Investors/Analysts Meet

    Company Update
    Update On Schedule Of The Investors/Analysts Meet To Be Held On August 25, 2026

    Akums Drugs and Pharmaceuticals Limited has informed the exchange about an update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of the Investors/Analysts Meet

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 27

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Link of audio recording of Investors/Analysts Conference Call

    Company Update
    Newspaper Publication
    Company Update
    Monitoring Agency Report

    Monitoring Agency Report for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation

    Company Update
    Press Release
    Result
    Un-Audited Financial Results For The Quarter Ended 30Th June, 2026

    Un-audited Financial Results for the Quarter ended 30th June, 2026

    Filed with BSE (scrip 544222); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Akums Drugs and Pharmaceuticals: common questions

    Answered from the figures on this page.

    Akums Drugs and Pharmaceuticals last traded at ₹716.15 (NSE, as of 18 Nov 2026). The last session moved it down 0.06%.

    Akums Drugs and Pharmaceuticals is valued at about ₹10,964 crore (NSE, as of 18 Nov 2026).

    Akums Drugs and Pharmaceuticals trades at a price-to-earnings ratio of 30.14 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Akums Drugs and Pharmaceuticals has traded between ₹409.30 and ₹838.80 over the past 52 weeks, to 18 Nov 2026. It is currently 71% of the way up that range.

    Akums Drugs and Pharmaceuticals (AKUMS) is classified under Pharma on this site's screener.